NCT04096638View on ClinicalTrials.gov

Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 23, 2019

Primary Completion Date

July 16, 2024

Study Completion Date

July 16, 2024

Conditions

MelanomaHead and Neck Squamous Cell CarcinomaSolid Tumor

Interventions

DRUG

SB 11285

SB 11285 2mg lyophilized powder for IV infusion

DRUG

Atezolizumab

1680 mg every 4 weeks

Trial Locations (2)

15232

UPMC Hillman Cancer Center, Pittsburgh

19111

Fox Chase Cancer Center, Philadelphia

All Listed Sponsors

lead

invoX Pharma Limited

INDUSTRY

NCT04096638 - Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter